Sunday, July 22, 2018 2:25:41 PM
http://www.mpadvisor.com/xyz/Cellceutix_160826.pdf
Prurisol – Clinical Development and Data in Psoriasis
CTIX-0001: Single-Dose, Crossover Pharmacokinetic and Bioequivalence Study Evaluating Oral Prurisol and Oral Abacavir Sulfate (Ziagen) in Healthy Volunteers.
Results: AUC values were comparable for both
Prurisol and Ziagen, (Figure 9) within 80% to
125% equivalence window, indicating equivalent systemic exposure. No serious adverse events or other significant adverse events occurred over the course of the study.
CTIX-0002 (Figure 10): A Ph2 trial of Prurisol in
patients with mild-to-moderate chronic plaque psoriasis
was completed in May 2016
•
Prurisol met the primary endpoint (a 2-point IGA reduction) in 35% of all patients who received a dose of 200mg per day.
Had one site, where investigator non-compliance was suspected to have occurred been removed from overall data analyses,
43% of patients in the 200mg dosing arm would have met the primary endpoint (Figure 11).
•
Among patients with the severest form of psoriasis studies, those having a baseline IGA score of 3 (“moderate”); the primary endpoint was met in 46% of patients who received 200mg per day. These data were derived from analyses of all patients.
•
Patients who received any dose of Prurisol, regardless of the treatment arm, had a 1-point IGA improvement.
•
Patients reported improved general skin condition, e.g., skin
felt moist and smoother
•
Prurisol was well-tolerated – just one Serious Adverse Event (SAE)
occurred and it was in the 50mg dose group.
•
PK results showed a dose-dependent
increase in exposure and maximum plasma
concentration of the drug. The elimination
half-life was similar in each of the three
dosing levels (50mg, 100mg, 200mg), with an average
of 1.3 hours. The clearance of the drug was also
similar across dosing levels, with an average of 80.1
liters per hour.
•
12 week Outperformed historical Investig
ator's Global Assessment (IGA) efficacy
data of competing drug in pipeline (C
F-101) and approved oral drug OTEZLA
(Figure 12).
18
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM